Innoviva (FRA:HVE) Cyclically Adjusted Revenue per Share: €3.81 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HVE Innoviva Inc FRA:HVE
88 GF Score
Price €18.40
GF Value €21.15
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Innoviva Cyclically Adjusted Revenue per Share?

Innoviva FRA:HVE +2.79% 88 Cyclically Adjusted Revenue per Share is €3.81 as of Jun. 2026. GuruFocus rates FRA:HVE with a GF Score™ of 88/100 and a GF Value™ of €21.15 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Innoviva's adjusted revenue per share for the three months ended in Jun. 2026 was €1.441. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €3.81 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Innoviva's average Cyclically Adjusted Revenue Growth Rate was 16.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 20.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 24.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 29.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Innoviva was 35.50% per year. The lowest was 7.20% per year. And the median was 30.55% per year.

As of today (2026-09-17), Innoviva's current stock price is €18.40. Innoviva's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €3.81. Innoviva's Cyclically Adjusted PS Ratio of today is 4.84.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Innoviva was 35.48. The lowest was 4.85. And the median was 10.13.


Innoviva  (FRA:HVE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Innoviva's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=18.40/3.805
=4.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Innoviva was 35.48. The lowest was 4.85. And the median was 10.13.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Innoviva Cyclically Adjusted Revenue per Share Related Terms


Innoviva Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Innoviva's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innoviva Cyclically Adjusted Revenue per Share Chart

Innoviva Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.66 1.96 2.37 2.88 3.33

Innoviva Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.31 3.43 3.52 3.66 3.81

FRA:HVE vs SLBT, MAZE, NVAX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Innoviva's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoviva Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Innoviva's Cyclically Adjusted PS Ratio falls into.


FRA:HVE
88GF Score
Innoviva Inc FRA:HVE
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innoviva Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Innoviva's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.441/333.9520*333.9520
=1.441

Current CPI (Jun. 2026) = 333.9520.

Innoviva Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.270 241.428 0.373
201612 0.363 241.432 0.502
201703 0.343 243.801 0.470
201706 0.468 244.955 0.638
201709 0.371 246.819 0.502
201712 0.520 246.524 0.704
201803 0.400 249.554 0.535
201806 0.522 251.989 0.692
201809 0.494 252.439 0.654
201812 0.644 251.233 0.856
201903 0.456 254.202 0.599
201906 0.530 256.143 0.691
201909 0.549 256.759 0.714
201912 0.632 256.974 0.821
202003 0.657 258.115 0.850
202006 0.659 257.797 0.854
202009 0.695 260.280 0.892
202012 0.668 260.474 0.856
202103 0.625 264.877 0.788
202106 0.860 271.696 1.057
202109 1.052 274.310 1.281
202112 1.189 278.802 1.424
202203 0.889 287.504 1.033
202206 1.505 296.311 1.696
202209 0.733 296.808 0.825
202212 0.975 296.797 1.097
202303 0.829 301.836 0.917
202306 1.185 305.109 1.297
202309 0.754 307.789 0.818
202312 0.977 306.746 1.064
202403 0.882 312.332 0.943
202406 1.535 314.175 1.632
202409 1.344 315.301 1.424
202412 1.060 315.605 1.122
202503 1.395 319.799 1.457
202506 1.084 322.561 1.122
202509 1.121 324.800 1.153
202512 1.189 324.054 1.225
202603 1.022 330.213 1.034
202606 1.441 333.952 1.441

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €3.81 mean?
Innoviva (FRA:HVE) has a Cyclically Adjusted Revenue per Share of €3.81 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Innoviva and its competitors.
Is Innoviva's Cyclically Adjusted Revenue per Share too high?
Innoviva's current Cyclically Adjusted Revenue per Share is €3.81. Overall, Innoviva has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innoviva's Cyclically Adjusted Revenue per Share compare to SLBT and MAZE?
Innoviva's Cyclically Adjusted Revenue per Share of €3.81 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Innoviva and its competitors. Innoviva's current Cyclically Adjusted Revenue per Share is €3.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innoviva stock overvalued right now?
Based on GuruFocus' analysis, Innoviva (FRA:HVE) is currently considered Modestly Undervalued. The stock's GF Value™ is €21.15, compared to a current price of €18.40 — trading 13% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €3.81. Innoviva's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Innoviva (FRA:HVE), the current Cyclically Adjusted Revenue per Share is €3.81 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innoviva (FRA:HVE) Overvalued in 2026?

Based on GuruFocus' analysis, Innoviva stock appears to be undervalued. The current stock price of €18.40 is trading 13% below its estimated GF Value™ of €21.15. GuruFocus considers Innoviva to be Modestly Undervalued.

Key valuation signals for FRA:HVE:

  • Cyclically Adjusted Revenue per Share: €3.81
  • GF Value™: €21.15 vs. price of €18.40 (13% below fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the FRA:HVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Innoviva Business Description

Other Exchanges INVA:USA
Address 1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
88GF Score

Get the complete analysis for FRA:HVE

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.40
Price
€21.15
GF Value